TNGX
Tango Therapeutics, Inc.
Key Financials
EPS (Diluted)
$-0.87
↑ 26.9%
Net Income
$-101594000
↑ 22.0%
Operating Income
$-111289000
↑ 23.6%
Total Liabilities
$52.5M
↓ 55.1%
Cash & Equivalents
$112.3M
↑ 61.5%
Shareholders' Equity
$346.2M
↑ 73.5%
Revenue
$62.4M
↑ 48.3%
Operating Cash Flow
$-138886000.00
↓ 5.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| SCHEDULE 13G/A | 5/13/2026 | View on SEC |
| SCHEDULE 13G/A | 5/11/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| SCHEDULE 13G | 5/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TNGX |
| Company Name | Tango Therapeutics, Inc. |
| CIK | 1819133 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (857) 320-4900 |